Immuno-oncology Mesodermal Progenitor Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell therapies for immuno-oncology require high cell doses due to the lack of immuno-modulatory properties in existing subtypes, leading to off-target side effects and difficulties in obtaining sufficient cells, particularly from bone marrow.
Innovation Solution
Identification and isolation of a novel immuno-oncology mesodermal progenitor (ioMP) cell with specific marker expression patterns, capable of modulating T cell responses and homing to target tissues, allowing for targeted therapy with lower cell doses and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high cell doses of MSCs are used to achieve therapeutic effects, then immune-modulatory properties are improved, but off-target side effects and volume-related side effects increase
Solution Approach 1:
The patent applies local quality by isolating a specific subset of mesenchymal progenitor cells with defined marker expression patterns (CD105+, CD73+, CD90+, HLA-DR-) that possess enhanced immune-modulatory properties. This creates a homogeneous cell population with concentrated therapeutic activity, allowing lower doses to achieve the same effect and reducing off-target side effects associated with heterogeneous MSC populations
2Reliability
If high cell doses of MSCs are used to achieve therapeutic effects, then immune-modulatory properties are improved, but volume-related side effects increase
Solution Approach 1:
By defining specific marker expression criteria (CD105+, CD73+, CD90+, HLA-DR-) and isolating cells meeting these criteria, the patent creates a concentrated population of cells with proven immune-modulatory capacity. This eliminates the need to administer large volumes of heterogeneous cells, directly reducing volume-related side effects while maintaining therapeutic efficacy
3Quantity of substance
If MSCs are obtained from bone marrow to achieve therapeutic effects, then cell sourcing is possible, but difficulty in obtaining large numbers of cells increases
Solution Approach 1:
The patent changes the sourcing parameter from bone marrow to peripheral blood mononuclear cells. This parameter change enables easier and less invasive cell collection while allowing for the isolation of sufficient numbers of immune-modulatory progenitor cells through defined marker expression, directly addressing the limitation of bone marrow sourcing
4Quantity of substance
If a mixture of MSC subtypes is used to achieve therapeutic effects, then cell availability is improved, but immuno-modulatory properties are reduced
Solution Approach 1:
The patent applies local quality by imposing strict marker expression criteria (CD105+, CD73+, CD90+, HLA-DR-) on the cell population. This creates a homogeneous subset of cells with confirmed immune-modulatory properties, eliminating the variability and reduced efficacy associated with heterogeneous MSC mixtures while maintaining sufficient cell availability through peripheral blood sourcing
Data Source
AI summary
The invention relates to immuno-oncology mesodermal progenitor (ioMP) cells and their use in therapy.